Loss of FHL1 induces an age-dependent skeletal muscle myopathy associated with myofibrillar and intermyofibrillar disorganization in mic
AbstractMyostatin is a TGFβ family ligand that reduces muscle mass. In cancer cells, TGFβ signalling...
<div><p>Facioscapulohumeral muscular dystrophy (FSHD) is an autosomal-dominant disease with no effec...
Objective: FHL1-related reducing body myopathy is an ultra-rare, X-linked dominant myopathy. In this...
Recent human genetic studies have provided evidences that sporadic or inherited missense mutations i...
A member of the four-and-a-half-LIM (FHL) domain protein family, FHL1, is highly expressed in human ...
FHL1 mutations cause several clinically heterogeneous myopathies, including reducing body myopathy (...
FHL1 mutations have been associated with various disorders that include reducing body myopathy (RBM)...
Skeletal muscle mass is maintained by a balance between two opposing processes, namely muscle growth...
Facioscapulohumeral muscular dystrophy (FSHD) is an autosomal-dominant disease with no effective tre...
Myostatin is a TGFβ family ligand that reduces muscle mass. In cancer cells, TGFβ signalling is incr...
Facioscapulohumeral muscular dystrophy (FSHD) is an autosomal-dominant disease with no effective tre...
Facioscapulohumeral muscular dystrophy (FSHD) is an autosomal-dominant disease with no effective tre...
Introduction: Reducing body myopathy is a rare X-linked myopathy. It is characterized by intracytopl...
Four and a half LIM domain protein 1 (FHL1) is the founding member of the FHL family of proteins cha...
Mutations in the FHL1 gene, and FHL1 protein deletion, are associated with rare hereditary myopathie...
AbstractMyostatin is a TGFβ family ligand that reduces muscle mass. In cancer cells, TGFβ signalling...
<div><p>Facioscapulohumeral muscular dystrophy (FSHD) is an autosomal-dominant disease with no effec...
Objective: FHL1-related reducing body myopathy is an ultra-rare, X-linked dominant myopathy. In this...
Recent human genetic studies have provided evidences that sporadic or inherited missense mutations i...
A member of the four-and-a-half-LIM (FHL) domain protein family, FHL1, is highly expressed in human ...
FHL1 mutations cause several clinically heterogeneous myopathies, including reducing body myopathy (...
FHL1 mutations have been associated with various disorders that include reducing body myopathy (RBM)...
Skeletal muscle mass is maintained by a balance between two opposing processes, namely muscle growth...
Facioscapulohumeral muscular dystrophy (FSHD) is an autosomal-dominant disease with no effective tre...
Myostatin is a TGFβ family ligand that reduces muscle mass. In cancer cells, TGFβ signalling is incr...
Facioscapulohumeral muscular dystrophy (FSHD) is an autosomal-dominant disease with no effective tre...
Facioscapulohumeral muscular dystrophy (FSHD) is an autosomal-dominant disease with no effective tre...
Introduction: Reducing body myopathy is a rare X-linked myopathy. It is characterized by intracytopl...
Four and a half LIM domain protein 1 (FHL1) is the founding member of the FHL family of proteins cha...
Mutations in the FHL1 gene, and FHL1 protein deletion, are associated with rare hereditary myopathie...
AbstractMyostatin is a TGFβ family ligand that reduces muscle mass. In cancer cells, TGFβ signalling...
<div><p>Facioscapulohumeral muscular dystrophy (FSHD) is an autosomal-dominant disease with no effec...
Objective: FHL1-related reducing body myopathy is an ultra-rare, X-linked dominant myopathy. In this...